US.BIIB · Biogen

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.8345505851107977,
        "turnoverUsdM": 195.8866175,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.BIIB",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 227.3186,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 0.5,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 5.7,
      "take_profit_price": 255.2562,
      "target_multiplier": 1.9,
      "technical_strength": 1.65,
      "take_profit_percent": 5.9
    },
    "positionPoints": 1.4,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.669101170221595,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 69.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 61.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 8
  },
  "market": {
    "ma20": 228.3885,
    "ma50": 221.6806,
    "close": 240.98,
    "prevClose": 243.1,
    "avgVolume20": 1236689,
    "volumeRatio": 0.66,
    "changePercent": -0.87
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 8,
    "details": {
      "ret_5d": 0.03500408023021073,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 8,
      "vcp_bonus": 0,
      "vol_ratio": 0.6396762567282571,
      "ret_points": 8,
      "vol_points": 0,
      "range_ratio": 0.5014193475324497,
      "volat_points": 0,
      "day_range_pct": 0.013154701634990431,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 0,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 69.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.2,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 44,
        "contribution": 2.2
      },
      {
        "raw": 14,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 70,
        "contribution": 14
      },
      {
        "raw": 6.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 41.33,
        "contribution": 6.2
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 6.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 66,
        "contribution": 6.6
      },
      {
        "raw": 20.9,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 69.67,
        "contribution": 20.9
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 61.9,
    "details": [
      "基本面分析總分: 2.2/5分",
      "資金流分析總分: 14/20分",
      "市場環境分析總分: 6.2/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 6.6/10分",
      "技術信號分析總分: 20.9/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 2.2,
      "資金流": 14,
      "市場環境": 6.2,
      "情緒分析": 6,
      "技術信號": 20.9,
      "風險管理": 6.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0,
          "turnoverUsdM": 195.8866175,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "良好",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 3.2,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.BIIB",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 2.4,
            "details": {
              "qqq": {
                "ma20": 739.07150265,
                "ma50": 726.75019988,
                "name": "QQQ",
                "close": 725.20001,
                "points": 0.4
              },
              "spy": {
                "ma20": 770.8804964,
                "ma50": 768.3371956999998,
                "name": "SPY",
                "close": 773.090027,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.8345505851107977,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 2.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 143070296,
                "url": "https://finnhub.io/api/news?id=ddc6e1144b1bd498cc2fca211d0682d66fc2d11daddebb95133578b52647a3d2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1792587618,
                "headline": "Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release"
              },
              {
                "id": 142827405,
                "url": "https://finnhub.io/api/news?id=c51779d3d7df77a8032713ac011bce19574478f7f4bfa06d8b2b04781d1ee56c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc. (NASDAQ:BIIB) closed at $225.71 on October 9. The stock has returned 30.5% during the last six months, compared to a 24.3% return for the Insider Monkey Billionaire Index and 15.1% for the State Street SPDR S&P 500 ETF Trust. Amgen Inc. (NASDAQ:AMGN) closed at $414.87 and has returned 18.6% over the same six […]",
                "category": "company",
                "datetime": 1791851470,
                "headline": "Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?"
              },
              {
                "id": 142825321,
                "url": "https://finnhub.io/api/news?id=db2d71f668cfe165e13f89cb01429985e98f0c46c6e9c5d7c7e8c751d51658d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.5% in the pre-market session after JPMorgan upgraded the stock to Overweight from Neutral with a $300 price target, raised from $210.",
                "category": "company",
                "datetime": 1791846183,
                "headline": "Biogen (BIIB) Stock Is Up, What You Need To Know"
              },
              {
                "id": 142825643,
                "url": "https://finnhub.io/api/news?id=2475f1deb3835cbd3a0765fb299f01eb86bba1652dad585ca19f2fb448e6f863",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen has bounced back on the market over the past year, and that kind of recovery puts fresh focus on a simple question for you as a shareholder or potential buyer: Is the current share price aligned with what the business may realistically produce in cash over time, based on its existing drugs and pipeline investments? Over the past 12 months Biogen has delivered a 58.6% share price gain, which raises the stakes on whether the recent momentum is fully grounded in its future cash...",
                "category": "company",
                "datetime": 1791843422,
                "headline": "Biogen (BIIB) Stock May Be 49% Below Fair Value As Lupus Data Loom"
              },
              {
                "id": 142824661,
                "url": "https://finnhub.io/api/news?id=5c5da9a40564805d54d1dc343a21338d71aaf0825323ce7c37fed45388edb71c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc. recently reported 52-week Phase 2 results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus, showing sustained improvements in skin disease activity and a generally well tolerated safety profile in patients who had not responded to or tolerated standard antimalarial therapies. The extended data, supported by the FDA’s Breakthrough Therapy Designation for litifilimab in CLE, reinforce its potential as a first-in-class, once-monthly therapy targeting BDCA2 on...",
                "category": "company",
                "datetime": 1791839401,
                "headline": "What Biogen (BIIB)'s 52-Week Litifilimab CLE Data Means For Shareholders"
              },
              {
                "id": 142823832,
                "url": "https://finnhub.io/api/news?id=677e3129c524cac7324c3c367bb91446ce3bb59dfccd4015298516546df7e2f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) is back in focus after releasing 52 week Phase 2 data for litifilimab in cutaneous lupus erythematosus, reporting sustained improvements in skin activity and a safety profile described as consistent with earlier studies. For investors, the litifilimab update comes after a solid run in the Biogen share price, with a 90 day share price return of 17.6% and a year-to-date share price gain of 26.9%. The 1 year total shareholder return of 56.0% contrasts with declines over the 3 and 5...",
                "category": "company",
                "datetime": 1791832278,
                "headline": "Biogen (BIIB) Could Be 5% Undervalued After 52 Week Lupus Data"
              },
              {
                "id": 142819094,
                "url": "https://finnhub.io/api/news?id=197cda554926ff4bffb812a468f6f11289dc392b1557e6f58842bb3211238b12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "According to The Fly, JPMorgan sees a potential market opportunity of more than $2 billion for Biogen’s felzartamab in antibody-mediated rejection.",
                "category": "company",
                "datetime": 1791804818,
                "headline": "BIIB Stock: JPMorgan Sees ‘Increasingly Compelling Catalyst Path’ For Biogen, Raises Price Target To $300"
              },
              {
                "id": 142667005,
                "url": "https://finnhub.io/api/news?id=48f11ac08d54b3e28cde258398358b2925e7aa8f85da3dab2e94259b8cf24501",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1791299406,
                "headline": "Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?"
              }
            ],
            "raw_source": [
              {
                "id": 143070296,
                "url": "https://finnhub.io/api/news?id=ddc6e1144b1bd498cc2fca211d0682d66fc2d11daddebb95133578b52647a3d2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1792587618,
                "headline": "Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release"
              },
              {
                "id": 143067862,
                "url": "https://finnhub.io/api/news?id=84a790847668ebb238e90facc3949ebb837ce3c4520939792a11d2dcc6cf93b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics advance late-stage drug pipelines, with key regulatory decisions and clinical trial results ahead.",
                "category": "company",
                "datetime": 1792584360,
                "headline": "The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics"
              },
              {
                "id": 143069839,
                "url": "https://finnhub.io/api/news?id=46c5a51c20d04bf20555bdeae73e41626773be092b9cb0aaba68f1c80fc4748b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254102883/image_2254102883.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen is rated Hold ahead of Q3 2026 earnings, with cautious optimism due to pipeline catalysts. Read more on BIIB stock here.",
                "category": "company",
                "datetime": 1792582262,
                "headline": "Biogen Q3 Earnings Preview: Grounds For Optimism, But Disappointment The Norm"
              },
              {
                "id": 143069179,
                "url": "https://finnhub.io/api/news?id=4268518ed28f3e77559414e68b7f1071953c46e77bf731c62334a41314eee89f",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "TD Cowen  analyst Phil Nadeau   maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $225 to $250.",
                "category": "company",
                "datetime": 1792576437,
                "headline": "TD Cowen Maintains Buy on Biogen, Raises Price Target to $250"
              },
              {
                "id": 143031147,
                "url": "https://finnhub.io/api/news?id=644dd6ec18767427693e2fe0f20c8e8cc753f3fb6de07218e5f1d48be6f44f23",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Investing.com -- RBC Capital has upgraded the Healthcare sector to Overweight from Market Weight, identifying 11 high-conviction stock ideas across therapeutics and non-therapeutics segments. The upgrade is supported by improving flows, positive earnings and sales revision profiles, and attractive valuations. RBC Head of Equity Strategy Lori Calvasina noted that Healthcare historically moves inversely to Technology’s relative performance versus the S&P 500, making it a natural destination when r",
                "category": "company",
                "datetime": 1792524424,
                "headline": "RBC Capital names top healthcare stocks as sector upgraded to overweight"
              },
              {
                "id": 143031680,
                "url": "https://finnhub.io/api/news?id=e11728fc8f5fa19627c71da56097d365124708caa38ac808ec39585063e67696",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "BIIB",
                "summary": "S&P 500 top movers for today's US session: Equifax led gainers at 11.46%, while General Motors led losers at -7.72%, ranked by percentage change.",
                "category": "company",
                "datetime": 1792514161,
                "headline": "S&P 500 Top Movers: Gainers and Losers From Today's US Session"
              },
              {
                "id": 143029159,
                "url": "https://finnhub.io/api/news?id=f479ad2df5936d859f53f8c84a798333a56d9d576d6101676e3408d578046dc5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.",
                "category": "company",
                "datetime": 1792503000,
                "headline": "4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now"
              },
              {
                "id": 143025571,
                "url": "https://finnhub.io/api/news?id=3bad8a224e7ed91550e1b91d6b1e29ab595863dc9bd082ea62f67e3e3620a61a",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Wells Fargo  analyst Mohit Bansal   maintains Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $250 to $310.",
                "category": "company",
                "datetime": 1792490147,
                "headline": "Wells Fargo Maintains Overweight on Biogen, Raises Price Target to $310"
              },
              {
                "id": 143006658,
                "url": "https://finnhub.io/api/news?id=128f392596d085f3a087a2d4ba623a478b80c0f19e3bbeaab0568482cbae6a3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "ABBV's neuroscience franchise targets nearly 16% revenue growth in Q3, with established drugs and newer Parkinson's therapies driving expansion.",
                "category": "company",
                "datetime": 1792411200,
                "headline": "AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results"
              },
              {
                "id": 143005875,
                "url": "https://finnhub.io/api/news?id=4ee66815d7416467592281892f43dbf5a66333fe7e9a275b9718728c2bd720d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Two oral presentations to highlight new 76-week data showing sustained proteinuria reduction and continued eGFR stabilization with a consistent long-term safety profileAdditional presentations to highlight nephrologist perspectives on gaps in current care practices and limited treatment options for antibody-mediated rejection (AMR)Presentations on the role of felzartamab, an investigational anti-CD38 monoclonal antibody, in multiple immune-mediated kidney diseases will also be featured CAMBRIDGE",
                "category": "company",
                "datetime": 1792409400,
                "headline": "Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week"
              },
              {
                "id": 143006438,
                "url": "https://finnhub.io/api/news?id=d54e48dd82215b7c03c46d22f4fb67787dc5f58177306ba2eae9c9a7c5e50530",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, including investigational felzartamab, at the American Society of",
                "category": "company",
                "datetime": 1792395141,
                "headline": "Biogen To Demonstrate Data, Additional Scientific Presentations From Its Nephrology Portfolio At American Society Of Nephrology Kidney Week"
              },
              {
                "id": 142954484,
                "url": "https://finnhub.io/api/news?id=566b777de47cf4258a817a60d513bcb7ddc7645f2b14d60abe037a9814ff7172",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "JPMorgan strongly reset its price target on the company’s attractive 2027 pipeline catalysts.",
                "category": "company",
                "datetime": 1792197420,
                "headline": "A kidney transplant milestone has Wall Street excited about Biogen"
              },
              {
                "id": 142950200,
                "url": "https://finnhub.io/api/news?id=b1fa0d753cf23ca6d1367c84b71f611b5973b1c128e237773dd2d8fd0e33782a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "It's another risk-off day for the broader market, with tech taking another tumble, thanks to a continued slide for semiconductor stocks.",
                "category": "company",
                "datetime": 1792172809,
                "headline": "Another Biotech IPO Pops on Rough Day for Broader Market"
              },
              {
                "id": 142944427,
                "url": "https://finnhub.io/api/news?id=9d0c8c9629cbfe7d9c78c8a89266ac9138c21201484802bea94c0a2c6af6bdc4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as \"ADPKD.\"",
                "category": "company",
                "datetime": 1792146600,
                "headline": "Biogen-backed Estuary nabs $93M for kidney disease gene therapy"
              },
              {
                "id": 142944885,
                "url": "https://finnhub.io/api/news?id=f91f403f3ffc3a12e9d0386f0f23990216287021ab63ad0404ebea0e9b7ed963",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192991654/image_2192991654.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen's Q3 earnings are due Oct 28. Explore FY2026 EPS guidance, Alzheimer’s revenue growth, and key risk/reward drivers—read now. Click for this BIIB update.",
                "category": "company",
                "datetime": 1792139325,
                "headline": "Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)"
              },
              {
                "id": 142914178,
                "url": "https://finnhub.io/api/news?id=9b328f3a9cf99637ab5347e872d1909f863d081eb03e438f7e2ad16fa8f84749",
                "image": "",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "",
                "category": "company",
                "datetime": 1792053514,
                "headline": "Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform"
              },
              {
                "id": 142848926,
                "url": "https://finnhub.io/api/news?id=9a21bc6679040d47af2b097ddec1264df35938cafcc4522683542e78d36acb1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), announced that Ming Wang (CEO) will participate in Boston CEO, November 2-3, 2026, at the Mandarin Oriental Hotel in Boston, MA. He will speak on a discussion panel entitled Competing in a New Global Playing Field.",
                "category": "company",
                "datetime": 1791896520,
                "headline": "Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026"
              },
              {
                "id": 142852675,
                "url": "https://finnhub.io/api/news?id=af92692e7d4eb3fa802ba818f7325fb8bdd1ff0aa1fa76b8095a64770bb2fa39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen is set to report its Q3 results soon, with analysts expecting a sharp double-digit decline in EPS.",
                "category": "company",
                "datetime": 1791889186,
                "headline": "Biogen’s Quarterly Earnings Preview: What You Need to Know"
              },
              {
                "id": 142827405,
                "url": "https://finnhub.io/api/news?id=c51779d3d7df77a8032713ac011bce19574478f7f4bfa06d8b2b04781d1ee56c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc. (NASDAQ:BIIB) closed at $225.71 on October 9. The stock has returned 30.5% during the last six months, compared to a 24.3% return for the Insider Monkey Billionaire Index and 15.1% for the State Street SPDR S&P 500 ETF Trust. Amgen Inc. (NASDAQ:AMGN) closed at $414.87 and has returned 18.6% over the same six […]",
                "category": "company",
                "datetime": 1791851470,
                "headline": "Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?"
              },
              {
                "id": 142825321,
                "url": "https://finnhub.io/api/news?id=db2d71f668cfe165e13f89cb01429985e98f0c46c6e9c5d7c7e8c751d51658d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.5% in the pre-market session after JPMorgan upgraded the stock to Overweight from Neutral with a $300 price target, raised from $210.",
                "category": "company",
                "datetime": 1791846183,
                "headline": "Biogen (BIIB) Stock Is Up, What You Need To Know"
              },
              {
                "id": 142825643,
                "url": "https://finnhub.io/api/news?id=2475f1deb3835cbd3a0765fb299f01eb86bba1652dad585ca19f2fb448e6f863",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen has bounced back on the market over the past year, and that kind of recovery puts fresh focus on a simple question for you as a shareholder or potential buyer: Is the current share price aligned with what the business may realistically produce in cash over time, based on its existing drugs and pipeline investments? Over the past 12 months Biogen has delivered a 58.6% share price gain, which raises the stakes on whether the recent momentum is fully grounded in its future cash...",
                "category": "company",
                "datetime": 1791843422,
                "headline": "Biogen (BIIB) Stock May Be 49% Below Fair Value As Lupus Data Loom"
              },
              {
                "id": 142824661,
                "url": "https://finnhub.io/api/news?id=5c5da9a40564805d54d1dc343a21338d71aaf0825323ce7c37fed45388edb71c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc. recently reported 52-week Phase 2 results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus, showing sustained improvements in skin disease activity and a generally well tolerated safety profile in patients who had not responded to or tolerated standard antimalarial therapies. The extended data, supported by the FDA’s Breakthrough Therapy Designation for litifilimab in CLE, reinforce its potential as a first-in-class, once-monthly therapy targeting BDCA2 on...",
                "category": "company",
                "datetime": 1791839401,
                "headline": "What Biogen (BIIB)'s 52-Week Litifilimab CLE Data Means For Shareholders"
              },
              {
                "id": 142823670,
                "url": "https://finnhub.io/api/news?id=5fcf98e656cace331f2453ea7672ef37921d4739c8dd76fe6128164881780509",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street He",
                "category": "company",
                "datetime": 1791834672,
                "headline": "Sector Update: Healthcare Stocks Rise Late Afternoon"
              },
              {
                "id": 142823832,
                "url": "https://finnhub.io/api/news?id=677e3129c524cac7324c3c367bb91446ce3bb59dfccd4015298516546df7e2f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) is back in focus after releasing 52 week Phase 2 data for litifilimab in cutaneous lupus erythematosus, reporting sustained improvements in skin activity and a safety profile described as consistent with earlier studies. For investors, the litifilimab update comes after a solid run in the Biogen share price, with a 90 day share price return of 17.6% and a year-to-date share price gain of 26.9%. The 1 year total shareholder return of 56.0% contrasts with declines over the 3 and 5...",
                "category": "company",
                "datetime": 1791832278,
                "headline": "Biogen (BIIB) Could Be 5% Undervalued After 52 Week Lupus Data"
              },
              {
                "id": 142823403,
                "url": "https://finnhub.io/api/news?id=7d346a60f670e8f9ddc8279296e8c4fd9cae67d242e655a952cce9bcd63808f9",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "BIIB",
                "summary": "Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.",
                "category": "company",
                "datetime": 1791831901,
                "headline": "Discover which S&P500 stocks are making waves on Monday."
              },
              {
                "id": 142823673,
                "url": "https://finnhub.io/api/news?id=d7b89a9724b6684eca2328ec43aa70627caa9eab7fbe881eb5a41bc920aa007e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen stock is upgraded to Overweight from Neutral at J.P. Morgan ahead of a slate of data readouts for compelling pipeline candidates.",
                "category": "company",
                "datetime": 1791825300,
                "headline": "Biogen Upgraded to Buy at J.P. Morgan. How the Stock Could Rise 28%."
              },
              {
                "id": 142822704,
                "url": "https://finnhub.io/api/news?id=24b33c08cf2e4246cd25e93cfa18caf87d1874dbf16960dd270daf649b1c0ae0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen stock is upgraded to Overweight from Neutral at J.P. Morgan ahead of a slate of data readouts for compelling pipeline candidates.",
                "category": "company",
                "datetime": 1791823020,
                "headline": "Biogen Stock Could Keep Gaining. A J.P. Morgan Upgrade Is Just the Beginning."
              },
              {
                "id": 139933529,
                "url": "https://finnhub.io/api/news?id=3f89e8879d586e5cd629005d198da398df5b90ad7a78af13079c92adb0c779d5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Spotify upgraded, Alibaba initiated: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1791812513,
                "headline": "Spotify upgraded, Alibaba initiated: Wall Street's top analyst calls"
              },
              {
                "id": 142819368,
                "url": "https://finnhub.io/api/news?id=07790595272c5552eeb9761d5fde2990c182b228c2dfe7de944815e11443ca2d",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "BIIB",
                "summary": "Get insights into the top gainers and losers in the S&P500 index of Monday's pre-market session.",
                "category": "company",
                "datetime": 1791808501,
                "headline": "Stay updated with the S&P500 stocks that are on the move in today's pre-market session."
              },
              {
                "id": 142819942,
                "url": "https://finnhub.io/api/news?id=07f905e4227277833637cc9692fb32fd055a9623d4c589916ec427d9029892db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Big banks kick off third-quarter earnings season tomorrow, and Wall Street analysts are already reshuffling their bets with a wave of surprise upgrades, downgrades, and fresh initiations across some of the market's most closely watched names.",
                "category": "company",
                "datetime": 1791807288,
                "headline": "Here Are Monday’s Top Wall Street Analyst Research Calls: Adobe, Biogen, First Solar, GoDaddy, Hubspot, Palantir Technologies, Robinhood Markets, Snowflake, TeraWulf, T-Mobile US and More"
              },
              {
                "id": 142819091,
                "url": "https://finnhub.io/api/news?id=471dbe8e44ee052eb30f6c569e370934be3284f5b7ba0d58c5ba598bcbe43d12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Investing.com -- JPMorgan lifted its rating for Biogen to Overweight from Neutral on Monday, pointing to a stronger run of clinical catalysts in 2027 and an improved long-term growth outlook.",
                "category": "company",
                "datetime": 1791805893,
                "headline": "JPMorgan gets bullish on Biogen ahead of 2027 catalysts"
              },
              {
                "id": 142819094,
                "url": "https://finnhub.io/api/news?id=197cda554926ff4bffb812a468f6f11289dc392b1557e6f58842bb3211238b12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "According to The Fly, JPMorgan sees a potential market opportunity of more than $2 billion for Biogen’s felzartamab in antibody-mediated rejection.",
                "category": "company",
                "datetime": 1791804818,
                "headline": "BIIB Stock: JPMorgan Sees ‘Increasingly Compelling Catalyst Path’ For Biogen, Raises Price Target To $300"
              },
              {
                "id": 142818618,
                "url": "https://finnhub.io/api/news?id=bf55334356bfe7e1144b5fcce0e6e447dc280a1bcb47e2c450075116711cad84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.",
                "category": "company",
                "datetime": 1791803943,
                "headline": "2 Surging  Stocks for Long-Term Investors and 1 We Brush Off"
              },
              {
                "id": 142821118,
                "url": "https://finnhub.io/api/news?id=9f18d7df53934337e115b97a5d65f47d70dca4bebe046ca327085a633ed5600c",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "JP Morgan  analyst Chris Schott   upgrades Biogen (NASDAQ:BIIB) from Neutral to Overweight and raises the price target from $210 to $300.",
                "category": "company",
                "datetime": 1791792520,
                "headline": "JP Morgan Upgrades Biogen to Overweight, Raises Price Target to $300"
              },
              {
                "id": 142822417,
                "url": "https://finnhub.io/api/news?id=a47529ceee0ab307e354aa282be6ff31574e4c12c718fdc96327ce61026e1cee",
                "image": "https://image.cnbcfm.com/api/v1/image/108353411-1787591101647-gettyimages-2271704570-US_STOCKS.jpeg?v=1791803914&w=1920&h=1080",
                "source": "CNBC",
                "related": "BIIB",
                "summary": "These are the stocks posting the largest moves in early trading.",
                "category": "company",
                "datetime": 1791790494,
                "headline": "Stocks making the biggest moves premarket: Salesforce, First Solar, Biogen & more"
              },
              {
                "id": 142791726,
                "url": "https://finnhub.io/api/news?id=9b65622705e3e362c7d28e05ef0dad0df47d77c3014d499293dee044acee525e",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "UBS  analyst Michael Yee   maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $240 to $270.",
                "category": "company",
                "datetime": 1791545871,
                "headline": "UBS Maintains Buy on Biogen, Raises Price Target to $270"
              },
              {
                "id": 142761821,
                "url": "https://finnhub.io/api/news?id=4d18da8f83cbf10d03b8e55007e78b17505bf058240a9eaa589964cca136f7d0",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $260 to $256.",
                "category": "company",
                "datetime": 1791453637,
                "headline": "RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $256"
              },
              {
                "id": 142694288,
                "url": "https://finnhub.io/api/news?id=bcf3d87d4790c76efdb9f81b82b264678fd2118cba6bdac7427e6d2884743781",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1687462580/image_1687462580.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Seeking Alpha welcomed 38 new analysts in September 2026. Read more on companies Qualcomm, Teladoc, and NewLake Capital Partners, as well as the TDAQ ETF here.",
                "category": "company",
                "datetime": 1791363600,
                "headline": "Stock Picks From Seeking Alpha's September 2026 New Analysts"
              },
              {
                "id": 142667876,
                "url": "https://finnhub.io/api/news?id=590d600038e76549d58cef880a58e000fde6a8bfa4d2054dc0ba7825564c1b97",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc (NASDAQ:BIIB, XETRA:IDP) is expected to report a slight third-quarter earnings per share beat at $2.14, against a consensus of $2.07, when it reports on October 28, says Jefferies. Revenue should be in line at $2.6 billion, with lower cost of goods sold and research and development...",
                "category": "company",
                "datetime": 1791306360,
                "headline": "Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says"
              },
              {
                "id": 142667005,
                "url": "https://finnhub.io/api/news?id=48f11ac08d54b3e28cde258398358b2925e7aa8f85da3dab2e94259b8cf24501",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1791299406,
                "headline": "Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 142662624,
                "url": "https://finnhub.io/api/news?id=dad5fb9983d775cad72c5c2338c949078af0797bb8002c1c8c00ef248e80b39b",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1791207317,
                "headline": "4 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 142623734,
                "url": "https://finnhub.io/api/news?id=5ef42e365d061cd004b39da4a3381f1dc657230a05e8d5dfce4caff85682c00e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2297903713/image_2297903713.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Design Therapeutics initiated at Hold: DT-216P2 shows early FA RESTORE-FA gains; watch Q4 '26/Q1 '27 catalysts and cash runway. Click for more on DSGN stock.",
                "category": "company",
                "datetime": 1791108485,
                "headline": "Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027"
              },
              {
                "id": 142591079,
                "url": "https://finnhub.io/api/news?id=3df0e72a2c6efea5ebc369c53b29a52821681a3ceabab71ef718925082530046",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Continued improvement: An increased response was seen in participants on litifilimab from week 24 through week 52, with more individuals achieving clear or almost clear skin (27.2%; CLA IGA 0-1) and improvements in disease activity (28.8%; CLASI-70) than at week 24 (19.0% and 21.7%, respectively)Rapid onset: Participants that switched from placebo to litifilimab experienced improvements in skin disease activity in as early as four weeks -- consistent with results seen in participants who started",
                "category": "company",
                "datetime": 1790954400,
                "headline": "Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus"
              },
              {
                "id": 142590792,
                "url": "https://finnhub.io/api/news?id=510ff0cf1c37661401ef523a1a0e96744fe98ab89cc4cc962cc7fdea3fb87a06",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "AbbVie's FDA approval of Juvmo expands its Parkinson's portfolio, with a commercial launch targeted for October 2026.",
                "category": "company",
                "datetime": 1790946000,
                "headline": "Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?"
              },
              {
                "id": 142614572,
                "url": "https://finnhub.io/api/news?id=c23deb453532ed87d821a806f371c227f93b0b12402bf0229ca8ec0e427ca878",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Biogen Inc. (NASDAQ:BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). The updated",
                "category": "company",
                "datetime": 1790940387,
                "headline": "Biogen Announces Data From Phase 2 Part Of Its Current AMETHYST Phase 2/3 Trial Of Litifilimab In Participants With Cutaneous Lupus Erythematosus Demonstrates 27.2% Of Patients At Week 52 Achieve Clinical Endpoint Of Clear Or Utmost Clear Skin; Litifilimab Seen To Be Generally Well Tolerated"
              },
              {
                "id": 142556747,
                "url": "https://finnhub.io/api/news?id=630adcfe3e0f85eada15d3e2b89c416d5339bdaebbf0eeb9bed4bcd20e1ce5ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.",
                "category": "company",
                "datetime": 1790854867,
                "headline": "1 Profitable Stock Worth Investigating and 2 We Ignore"
              },
              {
                "id": 142554444,
                "url": "https://finnhub.io/api/news?id=bece47a1e8fdf58a8f0d6edbe5160ce9e0d5db69bc8bd497806f738745132545",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS) announces the appointment of Linda Maxwell, M.D. and Mark DeLong as independent directors to its Board of Directors (the \"Board\"), effective today. The appointments follow the departures of Dr. Kyle Dempsey and Christine Elliott. Following these changes, the Board comprises eight directors, six of whom are independent.",
                "category": "company",
                "datetime": 1790852400,
                "headline": "HLS Therapeutics Announces Board of Directors Changes"
              },
              {
                "id": 142476966,
                "url": "https://finnhub.io/api/news?id=e56065f8d8bb86d533d9eb5479d567e55420ae19d538b5fd5211f4c034ab3811",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.",
                "category": "company",
                "datetime": 1790655819,
                "headline": "Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?"
              },
              {
                "id": 142468171,
                "url": "https://finnhub.io/api/news?id=0ffd656afbd32cbc60aff049296e4e6619a3faa131c3e4caa1bbd4259fd96270",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.",
                "category": "company",
                "datetime": 1790602860,
                "headline": "Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?"
              },
              {
                "id": 142426995,
                "url": "https://finnhub.io/api/news?id=ac4be69f7098cb364449374388a6fdcbed7c228428b62427c8d85bc387b1a8d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) and its peers.",
                "category": "company",
                "datetime": 1790376997,
                "headline": "Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack"
              },
              {
                "id": 142421742,
                "url": "https://finnhub.io/api/news?id=a07d38e192fa941e681aeeb3b0c0224f31aed5a0accfe1863cf64545f7a8922b",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1790256910,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 142362259,
                "url": "https://finnhub.io/api/news?id=753b4b7d69cafaf06738b203d4001dfd2442cbbc6f3b9d9f5df6199f75fc27d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Earlier this month, Eisai and Biogen secured Japanese approval for the at-home LEQEMBI Pen subcutaneous formulation for early Alzheimer’s disease, while Biogen also published Phase 3 VALIANT adolescent subgroup data showing EMPAVELI improved proteinuria and stabilized kidney function in rare complement-mediated kidney disorders. Together, these updates highlight Biogen’s push to make complex therapies more accessible in real-world settings, potentially broadening treatment reach in both...",
                "category": "company",
                "datetime": 1790173029,
                "headline": "How Investors May Respond To Biogen (BIIB) Advancing At-Home LEQEMBI Pen And Kidney Disease Data"
              },
              {
                "id": 142358333,
                "url": "https://finnhub.io/api/news?id=39daa93f12fb1aaac7873cc98266cd588a5e81be0a76291af138bb4bd2206c12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Key Stats for Novo Nordisk StockPrice change for Novo Nordisk stock in last 1 year: -35%$NVO Stock Price as of Sep. 22: $3952-Week High: $64$NVO Stock Price Target: $47What Happened?Novo Nordisk (NVO) stock dropped sharply on Monday after the company laid out new long-term goals that failed to convince investors it can hold its ground against fast-growing rivals in the weight loss drug market.",
                "category": "company",
                "datetime": 1790167286,
                "headline": "Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets"
              },
              {
                "id": 142356640,
                "url": "https://finnhub.io/api/news?id=d0db740160a2b965b635a57c05836424b88ac56d1b2e2902dfe87a4b0229596b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to recent selections by Amgen, Biogen, Eli Lilly and Company, and Regeneron. With more than 190 live customers and global commitments from 14 of the top 20 biopharmas, Vault CRM is the next generation of CRM, delivering new agentic and core capabilities to increase field productivity and effectiveness.",
                "category": "company",
                "datetime": 1790161380,
                "headline": "Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva"
              },
              {
                "id": 142356189,
                "url": "https://finnhub.io/api/news?id=bfb26be89ffc403aeab35e0567a6a80e6d03eb6f436a039191be7a0f63d38cd9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) is back in focus after publishing adolescent subgroup data from its Phase 3 VALIANT trial of EMPAVELI in rare kidney diseases, a catalyst that gives investors fresh clinical context around the stock. For context, Biogen’s recent clinical and product news has landed against a backdrop of stronger trading action, with a 1-day share price return of 2.87% on the latest close at US$225.36 and a 90-day share price return of 12.91%. Investors are weighing kidney and Alzheimer’s updates...",
                "category": "company",
                "datetime": 1790154918,
                "headline": "Biogen (BIIB) Posts New Kidney Trial Data, Is It Still 5% Undervalued?"
              },
              {
                "id": 142340644,
                "url": "https://finnhub.io/api/news?id=033972e3854745199d16a43e53d2bfecd4f709597d776ba31ba77bbd14999b14",
                "image": "https://image.cnbcfm.com/api/v1/image/108264668-1770841844066-gettyimages-2260574499-DOUSTDAR_INTERVIEW.jpeg?v=1770841930&w=1920&h=1080",
                "source": "CNBC",
                "related": "BIIB",
                "summary": "Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.",
                "category": "company",
                "datetime": 1790052809,
                "headline": "Novo defends diversification push as CEO eyes deals beyond obesity"
              },
              {
                "id": 142314832,
                "url": "https://finnhub.io/api/news?id=9621dec4437d024eba38c9bebeddc44fda5bb58df29c739bb6a87a7d6b6b34c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.",
                "category": "company",
                "datetime": 1790008800,
                "headline": "4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day"
              },
              {
                "id": 142314828,
                "url": "https://finnhub.io/api/news?id=90b2da6f1c010ca0c0afbc6e0da4e706ef8d938405a2b7b029e85696882d9e2d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Novo Nordisk (NYSE:NVO), the Danish drugmaker, saw its US-listed shares fall over 7% to $39.82 on Monday after new long-term targets failed to ease investor concerns about competition in the weight-loss drug market. The company said it aims to launch more than five multi-blockbuster drugs by...",
                "category": "company",
                "datetime": 1790006100,
                "headline": "Novo Nordisk shares plunge over 7% as new targets fail to reassure investors"
              },
              {
                "id": 142340649,
                "url": "https://finnhub.io/api/news?id=2059a9ef57dbfa8b8e82f89f3b9878fe009b8717089366ff4944c7fa9b32ff70",
                "image": "https://image.cnbcfm.com/api/v1/image/108363158-17894901612026-09-15t163359z_2080430281_rc2qjna3z3zx_rtrmadp_0_novo-nordisk-strategy-townhall.jpeg?v=1789490250&w=1920&h=1080",
                "source": "CNBC",
                "related": "BIIB",
                "summary": "The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.",
                "category": "company",
                "datetime": 1789964630,
                "headline": "Novo shares slide as drugmaker lays out post-Wegovy growth strategy"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 59,
            "discarded_article_count": 47
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.9,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 0.9,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.9,
            "vcp_reason": "站上MA50；升放量(近10日4日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 1187533.3333333333,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 1338690,
              "avg_vol_20": 1270760,
              "avg_vol_30": 1187533.3333333333,
              "range_pct_10": 0.12000991783550508,
              "range_pct_20": 0.12000991783550508,
              "range_pct_30": 0.1482280687193958,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 4,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.1272862516139899,
              "dist_to_20d_high": 0.01500098160641663,
              "down_shrink_days": 1,
              "breakout_level_20d": 244.64999,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.8096301791713328
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 1,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.8345505851107977,
              "turnoverUsdM": 195.8866175,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.BIIB",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 227.3186,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 0.5,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 5.7,
            "take_profit_price": 255.2562,
            "target_multiplier": 1.9,
            "technical_strength": 1.65,
            "take_profit_percent": 5.9
          },
          "positionPoints": 1.4,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.669101170221595,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.BIIB",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 6.8307,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.83
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 167.56
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.2001
    },
    "kdj": {
      "d": 71.71,
      "j": 95.79,
      "k": 79.74,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 67.42
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": -848175,
      "recentSlope": 491352.5,
      "previousSlope": -565330
    },
    "rsi": 70.17,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 220.5093,
      "position": "SAR喺價下",
      "distancePct": 8.49,
      "previousTrend": "上升"
    },
    "ma50": 221.6806,
    "macd": {
      "macd": 4.933060548853177,
      "trend": "強烈看漲",
      "signal": 3.513849847932738,
      "histogram": 1.4192107009204395
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 228.993,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 9
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.66,
      "score": 2,
      "avgVolume": 1236689,
      "currentVolume": 812875
    },
    "derived": {
      "ma20": 228.3885,
      "ma50": 221.6806,
      "prevClose": 243.1,
      "avgVolume10": 1290168,
      "avgVolume20": 1236689,
      "changePercent": -0.87,
      "avgVolumeForScore": 1236689
    },
    "ma_cross": {
      "ma20": 228.3885,
      "ma50": 221.6806,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 227.716,
      "prevMa50": 220.9388,
      "spreadPct": 3.03,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 215.713,
      "upper": 241.064,
      "position": "上半部"
    },
    "rsi_short": 77.81,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.66
    }
  }
}

{
  "close": 240.98,
  "volume": 812875,
  "changePercent": -0.87
}